An Observational Post-Authorization Safety Study (PASS) of Victrelis (Boceprevir) Among Chronic Hepatitis C Patients

Trial Profile

An Observational Post-Authorization Safety Study (PASS) of Victrelis (Boceprevir) Among Chronic Hepatitis C Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Sep 2016

At a glance

  • Drugs Boceprevir (Primary) ; Peginterferon; Ribavirin; Telaprevir
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck & Co; Schering-Plough
  • Most Recent Events

    • 30 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record .
    • 19 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
    • 29 May 2014 Planned End Date changed from 1 Mar 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top